FY2024 Earnings Estimate for CRSP Issued By Leerink Partnrs

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($5.05) per share for the year, up from their prior estimate of ($5.45). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.14) EPS and FY2025 earnings at ($5.53) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter last year, the firm posted ($1.41) EPS.

A number of other research analysts have also weighed in on the stock. JMP Securities reiterated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. Finally, Chardan Capital reissued a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $78.38.

CRISPR Therapeutics Stock Up 0.1 %

Shares of NASDAQ CRSP opened at $44.23 on Friday. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -15.63 and a beta of 1.68. The company’s 50-day simple moving average is $44.43 and its 200-day simple moving average is $47.88. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $91.10.

Insider Activity

In other news, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Market Strategies LLC purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $461,000. Capital Advisors Inc. OK grew its position in CRISPR Therapeutics by 8.1% in the 3rd quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares in the last quarter. Geode Capital Management LLC increased its stake in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. Granite Bay Wealth Management LLC purchased a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $2,375,000. Finally, State Street Corp grew its holdings in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.